Skip to content
Bending the Curve Trial by Trial
?

Back to Neuroblastoma and Wilms tumour

References: Neuroblastoma and Wilms tumour

104 sources cited on this page. Links open the primary source.

  1. Wilms M. Die Mischgeschwülste (part I: Die Mischgeschwülste der Niere; title of part I as cited by Raffensperger 2015). Leipzig: Arthur Georgi; 1899. Imprint as listed in the Wellcome Collection catalogue record (3 volumes). Source
  2. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med. 1948;238(23):787-93. PubMedDOI
    CiteLoading…
  3. Farber S. Chemotherapy in the treatment of leukemia and Wilms' tumor. JAMA. 1966;198(8):826-36. PubMed
    CiteLoading…
  4. Sullivan MP, Sutow WW, Cangir A, Taylor G. Vincristine sulfate in management of Wilms' tumor. Replacement of preoperative irradiation by chemotherapy. JAMA. 1967;202(5):381-4. PubMed
    CiteLoading…
  5. D'Angio GJ, Evans AE, Breslow N, Beckwith B, Bishop H, Feigl P, et al. The treatment of Wilms' tumor: Results of the national Wilms' tumor study. Cancer. 1976;38(2):633-46. PubMedDOI
    CiteLoading…
  6. Lemerle J, Voute PA, Tournade MF, Delemarre JF, Jereb B, Ahstrom L, et al. Preoperative versus postoperative radiotherapy, single versus multiple courses of actinomycin D, in the treatment of Wilms' tumor. Preliminary results of a controlled clinical trial conducted by the International Society of Paediatric Oncology (S.I.O.P.). Cancer. 1976;38(2):647-54. PubMedDOI
    CiteLoading…
  7. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumors: results from the First National Wilms' Tumor Study. Cancer. 1978;41(5):1937-48. PubMedDOI
    CiteLoading…
  8. D'Angio GJ, Evans A, Breslow N, Beckwith B, Bishop H, Farewell V, et al. The treatment of Wilms' tumor: results of the Second National Wilms' Tumor Study. Cancer. 1981;47(9):2302-11. PubMedDOI
    CiteLoading…
  9. Lemerle J, Voute PA, Tournade MF, Rodary C, Delemarre JF, Sarrazin D, et al. Effectiveness of preoperative chemotherapy in Wilms' tumor: results of an International Society of Paediatric Oncology (SIOP) clinical trial. J Clin Oncol. 1983;1(10):604-9. PubMedDOI
    CiteLoading…
  10. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121-4. PubMedDOI
    CiteLoading…
  11. Shimada H, Chatten J, Newton WA Jr, Sachs N, Hamoudi AB, Chiba T, et al. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst. 1984;73(2):405-16. PubMedDOI
    CiteLoading…
  12. Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985;313(18):1111-6. PubMedDOI
    CiteLoading…
  13. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol. 1988;6(12):1874-81. PubMedDOI
    CiteLoading…
  14. D'Angio GJ, Breslow N, Beckwith JB, Evans A, Baum H, deLorimier A, et al. Treatment of Wilms' tumor. Results of the Third National Wilms' Tumor Study. Cancer. 1989;64(2):349-60. PubMedDOI
    CiteLoading…
  15. Zantinga AR, Coppes MJ. Max Wilms (1867-1918): the man behind the eponym. Med Pediatr Oncol. 1992;20(6):515-8. PubMedDOI
    CiteLoading…
  16. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11(8):1466-77. PubMedDOI
    CiteLoading…
  17. Tournade MF, Com-Nougué C, Voûte PA, Lemerle J, de Kraker J, Delemarre JF, et al. Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. J Clin Oncol. 1993;11(6):1014-23. PubMedDOI
    CiteLoading…
  18. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy PE, Thomas PR, et al. Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1998;16(1):237-45. PubMedDOI
    CiteLoading…
  19. Green DM, Breslow NE, Beckwith JB, Finklestein JZ, Grundy P, Thomas PR, et al. Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1998;16(12):3744-51. PubMedDOI
    CiteLoading…
  20. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341(16):1165-73. PubMedDOI
    CiteLoading…
  21. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer. 1999;86(2):364-72. PubMed
    CiteLoading…
  22. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer. 1999;86(2):349-63. PubMed
    CiteLoading…
  23. Green DM, Breslow NE, Beckwith JB, Ritchey ML, Shamberger RC, Haase GM, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 2001;19(17):3719-24. PubMedDOI
    CiteLoading…
  24. Schilling FH, Spix C, Berthold F, Erttmann R, Fehse N, Hero B, et al. Neuroblastoma screening at one year of age. N Engl J Med. 2002;346(14):1047-53. PubMedDOI
    CiteLoading…
  25. Woods WG, Gao RN, Shuster JJ, Robison LL, Bernstein M, Weitzman S, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346(14):1041-6. PubMedDOI
    CiteLoading…
  26. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23(29):7312-21. PubMedDOI
    CiteLoading…
  27. Dome JS, Cotton CA, Perlman EJ, Breslow NE, Kalapurakal JA, Ritchey ML, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24(15):2352-8. PubMedDOI
    CiteLoading…
  28. Miller DR. A tribute to Sidney Farber-- the father of modern chemotherapy. Br J Haematol. 2006;134(1):20-6. PubMedDOI
    CiteLoading…
  29. Mitchell C, Pritchard-Jones K, Shannon R, Hutton C, Stevens S, Machin D, et al. Immediate nephrectomy versus preoperative chemotherapy in the management of non-metastatic Wilms' tumour: results of a randomised trial (UKW3) by the UK Children's Cancer Study Group. Eur J Cancer. 2006;42(15):2554-62. PubMedDOI
    CiteLoading…
  30. Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26(9):1504-10. PubMedDOI
    CiteLoading…
  31. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9(3):247-56. PubMedDOI
    CiteLoading…
  32. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289-97. PubMedDOI
    CiteLoading…
  33. Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009;27(7):1007-13. PubMedDOI
    CiteLoading…
  34. Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2009;27(2):298-303. PubMedDOI
    CiteLoading…
  35. Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010;363(14):1313-23. PubMedDOI
    CiteLoading…
  36. Shamberger RC, Anderson JR, Breslow NE, Perlman EJ, Beckwith JB, Ritchey ML, et al. Long-term outcomes for infants with very low risk Wilms tumor treated with surgery alone in National Wilms Tumor Study-5. Ann Surg. 2010;251(3):555-8. PubMedDOI
    CiteLoading…
  37. Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363(14):1324-34. PubMedDOI
    CiteLoading…
  38. Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Ann Surg. 2012;256(4):573-80. PubMedDOI
    CiteLoading…
  39. Strother DR, London WB, Schmidt ML, Brodeur GM, Shimada H, Thorner P, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012;30(15):1842-8. PubMedDOI
    CiteLoading…
  40. US Food and Drug Administration. BLA 125516 approval letter, Unituxin (dinutuximab), United Therapeutics Corporation; electronic signature date 10 March 2015. Source
  41. Pritchard-Jones K, Bergeron C, de Camargo B, van den Heuvel-Eibrink MM, Acha T, Godzinski J, et al. Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. Lancet. 2015;386(9999):1156-64. PubMedDOI
    CiteLoading…
  42. Raffensperger J. Max Wilms and his tumor. J Pediatr Surg. 2015;50(2):356-9. PubMedDOI
    CiteLoading…
  43. Gratias EJ, Dome JS, Jennings LJ, Chi YY, Tian J, Anderson J, et al. Association of Chromosome 1q Gain With Inferior Survival in Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group. J Clin Oncol. 2016;34(26):3189-94. PubMedDOI
    CiteLoading…
  44. Nakayama DK, Bonasso PC. The History of Multimodal Treatment of Wilms' Tumor. Am Surg. 2016;82(6):487-92. PubMed
    CiteLoading…
  45. European Medicines Agency. Unituxin (dinutuximab): European public assessment report page; marketing authorisation issued 14 August 2015, withdrawn 20 March 2017; page last updated 28 April 2017. Source
  46. Fernandez CV, Perlman EJ, Mullen EA, Chi YY, Hamilton TE, Gow KW, et al. Clinical Outcome and Biological Predictors of Relapse After Nephrectomy Only for Very Low-risk Wilms Tumor: A Report From Children's Oncology Group AREN0532. Ann Surg. 2017;265(4):835-840. PubMedDOI
    CiteLoading…
  47. Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18(4):500-514. PubMedDOI
    CiteLoading…
  48. Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, et al. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncol. 2017;18(7):946-957. PubMedDOI
    CiteLoading…
  49. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580-2587. PubMedDOI
    CiteLoading…
  50. van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwängler R, Verschuur AC, et al. Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol. Nat Rev Urol. 2017;14(12):743-752. PubMedDOI
    CiteLoading…
  51. Dix DB, Seibel NL, Chi YY, Khanna G, Gratias E, Anderson JR, et al. Treatment of Stage IV Favorable Histology Wilms Tumor With Lung Metastases: A Report From the Children's Oncology Group AREN0533 Study. J Clin Oncol. 2018;36(16):1564-1570. PubMedDOI
    CiteLoading…
  52. Fernandez CV, Mullen EA, Chi YY, Ehrlich PF, Perlman EJ, Kalapurakal JA, et al. Outcome and Prognostic Factors in Stage III Favorable-Histology Wilms Tumor: A Report From the Children's Oncology Group Study AREN0532. J Clin Oncol. 2018;36(3):254-261. PubMedDOI
    CiteLoading…
  53. Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(12):1617-1629. PubMedDOI
    CiteLoading…
  54. Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, et al. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018;8(1):14445. PubMedDOI
    CiteLoading…
  55. Dix DB, Fernandez CV, Chi YY, Mullen EA, Geller JI, Gratias EJ, et al. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report. J Clin Oncol. 2019;37(30):2769-2777. PubMedDOI
    CiteLoading…
  56. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019;322(8):746-755. PubMedDOI
    CiteLoading…
  57. US Food and Drug Administration. BLA 761171 accelerated approval letter, Danyelza (naxitamab-gqgk), Y-mAbs Therapeutics; electronic signature date 25 November 2020. Source
  58. Mody R, Yu AL, Naranjo A, Zhang FF, London WB, Shulkin BL, et al. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. J Clin Oncol. 2020;38(19):2160-2169. PubMedDOI
    CiteLoading…
  59. Berthold F, Spix C, Erttmann R, Hero B, Michaelis J, Treuner J, et al. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial. JNCI Cancer Spectr. 2021;5(4). PubMedDOI
    CiteLoading…
  60. Dome JS, Mullen EA, Dix DB, Gratias EJ, Ehrlich PF, Daw NC, et al. Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor. J Natl Compr Canc Netw. 2021;19(8):978-985. PubMedDOI
    CiteLoading…
  61. Garaventa A, Poetschger U, Valteau-Couanet D, Luksch R, Castel V, Elliott M, et al. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23):2552-2563. PubMedDOI
    CiteLoading…
  62. Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. J Clin Oncol. 2021;39(29):3229-3241. PubMedDOI
    CiteLoading…
  63. Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, et al. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res. 2021;27(8):2179-2189. PubMedDOI
    CiteLoading…
  64. US Food and Drug Administration. NDA 215500 approval letter, Iwilfin (eflornithine) tablets, USWM, LLC; electronic signature date 13 December 2023. Source
  65. US Food and Drug Administration. FDA approves eflornithine for adult and pediatric patients with high-risk neuroblastoma; page content current as of 14 December 2023. Source
  66. US Food and Drug Administration. Final summary minutes of the Oncologic Drugs Advisory Committee meeting, 4 October 2023 (NDA 215500, eflornithine); minutes approved 9 November 2023. Source
  67. Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, et al. Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22(6):413-433. PubMedDOI
    CiteLoading…
  68. Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al. Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial. J Clin Oncol. 2024;42(10):1135-1145. PubMedDOI
    CiteLoading…
  69. National Cancer Institute. Cancer in Children and Adolescents (fact sheet). Page updated 27 August 2024; accessed 20 October 2026. https://www.cancer.gov/types/childhood-cancers/child-adolescent-cancers-fact-sheet Source
  70. Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, et al. Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons. J Clin Oncol. 2024;42(1):90-102. PubMedDOI
    CiteLoading…
  71. Kumar Upadhyay A, Prakash A, Kumar A, Jena S, Sinha N, Sharma S. Dr. Sidney Farber (1903-1973): Founder of Pediatric Pathology and the Father of Modern Chemotherapy. Cureus. 2024;16(8):e68286. PubMedDOI
    CiteLoading…
  72. Balis F, Green DM, Armstrong A, Aye J, Benedetti D, Brown B, et al. Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025;23(8):319-342. PubMedDOI
    CiteLoading…
  73. Dholaria H, Naranjo A, Zhang FF, London WB, Diller L, Shamberger RC, et al. Long-Term Outcome of Young Infants With Suspected Neuroblastoma following Observation as Primary Therapy: A Report From the Children's Oncology Group. Pediatr Blood Cancer. 2025;72(8):e31829. PubMedDOI
    CiteLoading…
  74. European Medicines Agency. Ifinwil (eflornithine): application withdrawn 18 July 2025; page last updated 25 July 2025. Source
  75. European Medicines Agency. Qarziba (dinutuximab beta): European public assessment report page; European Commission marketing authorisation 8 May 2017 (as Dinutuximab beta Apeiron); page last updated 26 November 2025. Source
  76. Mora J, Chan GCF, Morgenstern DA, Amoroso L, Nysom K, Faber J, et al. The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial. Nat Commun. 2025;16(1):1636. PubMedDOI
    CiteLoading…
  77. National Cancer Institute. Neuroblastoma Treatment (PDQ), Health Professional Version. Bethesda (MD): National Cancer Institute; latest update listed on the page 28 April 2025. Section on screening (general population). Source
  78. PDQ Pediatric Treatment Editorial Board. Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ), Health Professional Version. Bethesda (MD): National Cancer Institute; page updated 15 April 2025; accessed 20 October 2026. https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq Source
  79. ClinicalTrials.gov. NCT00002611 (organisation study ID 9440; secondary ID NWTS-5). Registry record, accessed 20 October 2026. NCT00002611
  80. ClinicalTrials.gov. NCT00002803 (NB95-S; org id CDR0000064903). Registry record, API v2, accessed 20 October 2026. NCT00002803
  81. ClinicalTrials.gov. NCT00003093 (A3961). Registry record, API v2, accessed 20 October 2026. NCT00003093
  82. ClinicalTrials.gov. NCT00003119 (P9641). Registry record, API v2, accessed 20 October 2026. NCT00003119
  83. ClinicalTrials.gov. NCT00017225 (GPOH-GERMANY-NB97). Registry record, API v2, accessed 20 October 2026. NCT00017225
  84. ClinicalTrials.gov. NCT00026312 (ANBL0032). Registry record, accessed 20 October 2026. NCT00026312
  85. ClinicalTrials.gov. NCT00047138 (secondary ID SIOP-WT-2001). Registry record, accessed 20 October 2026. NCT00047138
  86. ClinicalTrials.gov. NCT00352534 (organisation study ID AREN0532). Registry record, accessed 20 October 2026. NCT00352534
  87. ClinicalTrials.gov. NCT00379340 (organisation study ID AREN0533). Registry record, accessed 20 October 2026. NCT00379340
  88. ClinicalTrials.gov. NCT00445718 (ANBL00P2). Registry record, API v2, accessed 20 October 2026. NCT00445718
  89. ClinicalTrials.gov. NCT00567567 (ANBL0532). Registry record, accessed 20 October 2026. NCT00567567
  90. ClinicalTrials.gov. NCT00904241 (ANBL00B1). Registry record, API v2, accessed 20 October 2026. NCT00904241
  91. ClinicalTrials.gov. NCT01704716 (HR-NBL-1.8 / SIOPEN). Registry record, accessed 20 October 2026. NCT01704716
  92. ClinicalTrials.gov. NCT01767194 (ANBL1221). Registry record, accessed 20 October 2026. NCT01767194
  93. ClinicalTrials.gov. NCT02176967 (COG ANBL1232). Registry record, accessed 21 October 2026. NCT02176967
  94. ClinicalTrials.gov. NCT02308527 (BEACON). Registry record, accessed 20 October 2026. NCT02308527
  95. ClinicalTrials.gov. NCT02395666 (NMTRC003B). Registry record, accessed 20 October 2026. NCT02395666
  96. ClinicalTrials.gov. NCT03126916 (COG ANBL1531). Registry record, accessed 21 October 2026. NCT03126916
  97. ClinicalTrials.gov. NCT03363373 (Study 201). Registry record, accessed 20 October 2026. NCT03363373
  98. ClinicalTrials.gov. NCT04221035 (HR-NBL2 / SIOPEN). Registry record, accessed 21 October 2026. NCT04221035
  99. ClinicalTrials.gov. NCT06172296 (COG ANBL2131). Registry record, accessed 21 October 2026. NCT06172296
  100. ClinicalTrials.gov. NCT06401330 (COG AREN2231). Registry record, accessed 21 October 2026. NCT06401330
  101. FDA. Ongoing | Cancer Accelerated Approvals. Listing, content current as of 19 October 2026 (accessed 20 October 2026). Source
  102. U.S. Food and Drug Administration, Oncology Center of Excellence. Pediatric Oncology Drug Approvals (table current as of February 2026; page content current as of 03/03/2026). Accessed 2026-10-20. Source
  103. US Food and Drug Administration. Verified Clinical Benefit | Cancer Accelerated Approvals. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. Content current as of 16 October 2026. Source
  104. Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, et al. Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. J Clin Oncol. 2026;44(3):176-187. PubMedDOI
    CiteLoading…